Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 3/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | TK1 | P04183 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20215653 | 0.87 | DAO (0.46) | SMN1; SMN2DAOCRBNTK1PDE4A | |
| SCHEMBL16434593 | 0.83 | GRIA1 (0.41) | DAOCRBNMAPK1CYP2C9KMT2A | |
| SCHEMBL10137841 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2DAOGRIN2DGRIN3BGRIN1 | |
| SCHEMBL17041835 | 0.77 | TDP1 (0.53) | SMN1; SMN2DAOGRIN2DGRIN3BGRIN1 | |
| SCHEMBL19841641 | 0.77 | GRIN2D (0.39) | SMN1; SMN2DAOGRIN2DGRIN3BGRIN1 | |
| SCHEMBL23957853 | 0.77 | MAPK1 (0.43) | SMN1; SMN2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL11335744 | 0.77 | TK1 (0.40) | SMN1; SMN2DAOGRIN2DGRIN3BGRIN1 | |
| SCHEMBL13320099 | 0.76 | — | — | |
| SCHEMBL25823753 | 0.75 | TK1 (0.40) | SMN1; SMN2DAOGRIN2DGRIN3BGRIN1 | |
| SCHEMBL14438657 | 0.75 | ALDH1A1 (0.46) | SMN1; SMN2CYP2C9KMT2AMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230309833-A1 | METHODS AND MATERIALS FOR USING [18F]-F-ARAG IN CARDIAC IMAGING | CELLSIGHT TECHNOLOGIES INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2022219636-A1 | ANTI-VIRAL AND ANTI-TUMORAL COMPOUNDS, AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-10-20 | — | — | WO | disclosed |
| WO-2021226327-A1 | NUCLEOTIDE CLEAVABLE LINKERS WITH RIGID SPACERS AND USES THEREOF | Singular Genomics Systems, Inc. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-20210187133-A1 | Compounds and Methods of Making Compounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-06-24 | — | — | US | disclosed |
| US-9173893-B2 | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections | COCRYSTAL PHARMA, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150118157-A1 | Compounds and Methods of Making Compounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-04-30 | — | — | US | disclosed |
| US-20150118157-A1 | Compounds and Methods of Making Compounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-04-30 | — | — | US | disclosed |
| US-9011817-B2 | Compounds and methods of making compounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-04-21 | — | — | US | disclosed |
| US-9011817-B2 | Compounds and methods of making compounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140066395-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2014-03-06 | — | — | US | disclosed |
| US-8269015-B2 | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-18 | — | — | US | disclosed |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110306592-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-15 | — | — | US | disclosed |
| US-20110059014-A1 | COMPOUNDS AND METHODS OF MAKING COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-10 | — | — | US | disclosed |
| US-20110059014-A1 | COMPOUNDS AND METHODS OF MAKING COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-10 | — | — | US | disclosed |
| US-20100267688-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150118157-A1 | Compounds and Methods of Making Compounds | MCL1, TOP2B, TOP1 | SMN1; SMN2 374/4885DAO 3262/4885GRIN2D 1076/4885 |
| US-20210187133-A1 | Compounds and Methods of Making Compounds | MCL1, TOP1, TOP2B | SMN1; SMN2 322/4885DAO 3472/4885GRIN2D 1236/4885 |
| US-20110059014-A1 | COMPOUNDS AND METHODS OF MAKING COMPOUNDS | MCL1, TOP2B, TOP1 | SMN1; SMN2 374/4885DAO 3262/4885GRIN2D 1076/4885 |
| US-20140066395-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | PNP, HAVCR2, TYMP | SMN1; SMN2 1466/4885DAO 1519/4885GRIN2D 3750/4885 |
| US-20110306592-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | SMN1; SMN2 3296/4885DAO 1842/4885GRIN2D 1592/4885 |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | SMN1; SMN2 1231/4885DAO 837/4885GRIN2D 4749/4885 |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | PNP, HAVCR2, TYMP | SMN1; SMN2 1466/4885DAO 1519/4885GRIN2D 3750/4885 |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCRL2 | SMN1; SMN2 4230/4885DAO 2753/4885GRIN2D 900/4885 |
| US-20100267688-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | SMN1; SMN2 3322/4885DAO 2519/4885GRIN2D 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.